Skip to main content

Table 1 Patient characteristics: Immunohistochemical staining for oestrogen receptors (ER) (ER alpha, ER beta) and progesterone receptors (PR) (PR-A and PR-B) were performed and analysed as previously published by our research group[25]

From: Immunosuppressive Glycodelin A is an independent marker for poor prognosis in endometrial cancer

Grade (%)

1

147 (51.2)

(n = 287)

2

93 (32.4)

 

3

47 (16.4)

FIGO stage (%)

I

219 (75.0)

(n = 292)

II

21 (7.2)

 

III

44 (15.1)

 

IV

8 (2.7)

Histology (%)

Endometrioid

212 (72.6)

(n = 292)

Serous

23 (7.9)

 

Clear cell

5 (1.7)

 

Mucinous

12 (4.1)

 

Squamous cell

1 (0.3)

 

Mixed

34 (11.6)

 

Undifferentiated

5 (1.7)

Patient age ± sem [y] (range)

 

65.1 ± 0.6 (35.6-88.1)

Deaths (%)

 

160 (54.8)

Survival ± sem [y] (95% CI)

 

13.6 ± 0.5 (12.6-14.6)

Follow up ± sem [y] (95% CI)

 

13.8 ± 0.3 (13.1-14.5)

Glycodelin (%) (n = 291)

Low

79 (27.1)

 

Intermediate

152 (52.2)

 

High

60 (20.6)

Glycodelin A (%) (n = 289)

Low

82 (28.4)

 

Intermediate

181 (62.6)

 

High

26 (9.0)

ER alpha (%) (n = 292)

Positive

133 (45.5)

ER beta (%) (n = 292)

Positive

40 (13.7)

PRA (%) (n = 292)

Positive

121 (41.4)

PRB (%) (n = 292)

Positive

134 (45.9)

Co-morbidities

Hypertension (%)

116 (39.7)

 

Diabetes (%)

33 (11.3)

 

Obesity (%)

89 (30.5)

Lymphangiosis (%) (n = 292)

Positive

27 (9.2)

 

Negative

263 (90.1)

 

Unknown

2 (0.7)

Hemangiosis (%) (n = 292)

Positive

8 (2.7)

 

Negative

281 (96.2)

 

Unknown

3 (1.0)

Radiotherapy (%) (n = 292)

Yes

116 (39.7)

 

No

170 (58.2)

 

Declined

6 (2.1)

Chemotherapy (%) (n = 292)

Yes

7 (2.4)

 

No

283 (96.9)

 

Declined

2 (0.7)